Kangtai Bio’s third-quarter revenue misses Goldman Sachs expectations, while lower impairments lift net profit above forecasts
A declining birth rate and industry competition weighed on revenue. Overseas business grew rapidly but remained a small share of the total. Goldman Sachs cut its revenue forecasts for the next three years, raised its net profit forecasts and maintained a Neutral rating.
Original source：Goldman SachsFirst published on Unhidea：Original source date：
Key takeaway
Kangtai Bio’s third-quarter profit exceeded Goldman Sachs’ expectations mainly because impairments were lower than expected, but pressure on revenue and limited near-term contributions from new products keep the bank cautious on the growth outlook.
Why did revenue miss expectations while profit beat them in the third quarter?
Kangtai Bio reported third-quarter 2026 revenue of 568 million yuan, down 15% year on year and below Goldman Sachs’ earlier forecast of 663 million yuan. The bank believes a declining birth rate and intensifying industry competition put pressure on revenue.
Net profit for the same period was 45 million yuan, up 269% year on year and above Goldman Sachs’ forecast of 26 million yuan, mainly because impairments of both receivables and inventory were lower than the bank expected. The profit beat coincided with the revenue miss.
Can overseas growth and new vaccines drive near-term expansion?
Third-quarter overseas revenue rose 89% year on year and 130% quarter on quarter, but accounted for only about 8% of total revenue and remained relatively small in absolute terms.
The company believes its recently approved influenza vaccine and adsorbed tetanus vaccine will provide some support for growth. Goldman Sachs, however, expects limited incremental revenue from the two products in the near term, making substantial short-term expansion difficult.
How has Goldman Sachs revised its earnings forecasts?
Goldman Sachs cut its revenue forecasts for 2026 through 2028 by 3.3%, 3.7% and 4.0%, respectively, to 2.514 billion yuan, 2.889 billion yuan and 3.277 billion yuan.
Despite the revenue cuts, the bank raised its net profit forecasts for the same years by 9.1%, 2.4% and 3.0%, respectively, to 101 million yuan, 218 million yuan and 276 million yuan. The revisions reflect the impact of lower-than-expected impairments in these results.
Which products shape the medium-term assessment?
Goldman Sachs expects the sales ramp-up of the 13-valent pneumococcal vaccine and human diploid cell rabies vaccine to more than offset the decline in COVID vaccine revenue. Near-term incremental contributions from influenza and tetanus vaccines are insufficient to change its cautious view on short-term expansion.
The company’s forward price-to-earnings ratio for the coming year is in the lowest quartile of its range over the past five years, but Goldman Sachs maintains its Neutral rating and 12-month price target of 14 yuan, seeking evidence that the company can continue to offset the effects of COVID vaccines and policy measures such as anti-corruption initiatives.
The bank identifies the launches of the pentavalent vaccine and 20-valent pneumococcal vaccine, as well as the introduction of new products from multinational pharmaceutical companies, as key catalysts. Downside risks include weaker-than-expected sales of the 13-valent pneumococcal vaccine and rabies vaccine, and the inclusion of pneumococcal vaccines in volume-based procurement.
